Riverhead Capital Management’s Myriad Genetics MYGN Stock Holding History

Riverhead Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$238K	Buy	8,298 +400	+5%	+$11.7K	0.01%	1057
2019 Q2	$219K	Buy	7,898 +400	+5%	+$11.3K	0.01%	1110
2019 Q1	$249K	Hold	7,498	–	–	0.01%	1022
2018 Q4	$218K	Hold	7,498	–	–	0.01%	1031
2018 Q3	$345K	Buy	7,498 +400	+6%	+$17.8K	0.01%	938
2018 Q2	$265K	Hold	7,098	–	–	0.01%	954
2018 Q1	$210K	Buy	7,098 +1,100	+18%	+$37.2K	0.01%	1046
2017 Q4	$206K	Buy	5,998 +1,000	+20%	+$33.7K	0.01%	1056
2017 Q3	$181K	Buy	4,998 +837	+20%	+$23.9K	0.01%	1030
2017 Q2	$107K	Buy	4,161 +1,861	+81%	+$39.5K	0.01%	1193
2017 Q1	$44K	Buy	+2,300	New	+$40.8K	﹤0.01%	1299

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Riverhead Capital Management's MYGN Position: Q3 2019 in Review

Riverhead Capital Management increased its Myriad Genetics (MYGN) stake by 5.1% in Q3 2019, buying an estimated $11.7K and bringing the position to 8,298 shares worth $238K. The position accounts for 0.01% of the portfolio, ranked #1057.

Riverhead Capital Management first reported a position in MYGN in Q1 2017 and has held it in 11 quarters since. The position peaked at $345K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Riverhead Capital Management held 8,298 shares of Myriad Genetics worth $238K as of Q3 2019.
Riverhead Capital Management bought 400 Myriad Genetics shares in Q3 2019, an estimated $11.7K.
Myriad Genetics made up 0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1057 holding.
Riverhead Capital Management first reported a position in Myriad Genetics in Q1 2017 and has held it in 11 quarters since.
Riverhead Capital Management's Myriad Genetics position peaked at $345K in Q3 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.